Enrichment designs using placebo nonresponders

被引:4
|
作者
Benda, Norbert [1 ,2 ]
Haenisch, Britta [1 ,3 ,4 ]
机构
[1] Fed Inst Drugs & Med Devices BfArM, Res Dept, Bonn, Germany
[2] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany
[3] German Ctr Neurodegenerat Dis DZNE, Populat Hlth Sci, Bonn, Germany
[4] Univ Bonn, Ctr Translat Med, Bonn, Germany
关键词
drug approval; enrichment design; placebo response; sequential parallel design; MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND; CLINICAL-TRIALS; ZIPRASIDONE MONOTHERAPY; 12-WEEK; SYMPTOMS; EFFICACY; OUTCOMES; THERAPY;
D O I
10.1002/pst.1992
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Enrichment designs that select placebo nonresponders have gained much attention during the last years in areas with high placebo response rates, eg, in depression. Proposals were made that re-randomize patients who did not respond to placebo during a first study phase as the sequential parallel design (SPD). This design uses in a second phase an enriched patient population where the treatment effect is expected to be more pronounced. This may be problematic if an effect in the overall population is claimed. Proposals were made to combine the treatment effects in the overall population from study phase 1 and the enriched population from study phase 2, alleviating but not solving the issue of a potential selection bias. This paper shows how this bias corresponding to the effect difference between the overall population and the enriched population depends on the variability of a potential subject-by-treatment interaction. Sample sizes are given, which lead to a significant result in the combining test with a given probability if actually the average effect in the overall population is zero. If, on the other hand, no subject-by-treatment interaction is given, the enrichment is shown to be inefficient. We conclude that enrichment designs using placebo nonresponders are not able to claim a positive average effect in the overall population if a subject-by-treatment interaction cannot be excluded. It cannot be used to demonstrate positive efficacy in the overall population in a pivotal phase III trial but may be used in early phases to demonstrate varying treatment effects between patients.
引用
收藏
页码:303 / 314
页数:12
相关论文
共 50 条
  • [1] SPECIAL STUDY DESIGNS - EARLY ESCAPE, ENRICHMENT, STUDIES IN NONRESPONDERS
    TEMPLE, RJ
    COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 1994, 23 (02) : 499 - 531
  • [2] The plan of enrichment designs for dealing with high placebo response
    Zhang, Xiangmin
    Chen, Yeh-Fong
    Tamura, Roy
    PHARMACEUTICAL STATISTICS, 2018, 17 (01) : 25 - 37
  • [3] Creating Placebo Nonresponders in the Lab
    Benedetti, Fabrizio
    Arduino, Claudia
    Shaibani, Aziz
    Thoen, Wilma
    JOURNAL OF PAIN, 2024, 25 (04): : 962 - 973
  • [4] Role of placebo factors in clinical trials with special focus on enrichment designs
    Staud, Roland
    Price, Donald D.
    PAIN, 2008, 139 (02) : 479 - 480
  • [5] Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: Application to antidepressant trials
    Boessen, Ruud
    Knol, Mirjam J.
    Groenwold, Rolf H. H.
    Grobbee, Diederick E.
    Roes, Kit C. B.
    CLINICAL TRIALS, 2012, 9 (05) : 578 - 587
  • [6] Placebo responders and nonresponders: what's new?
    Frisaldi, Elisa
    Shaibani, Aziz
    Benedetti, Fabrizio
    PAIN MANAGEMENT, 2018, 8 (06) : 405 - 408
  • [7] Using Bayesian modeling in frequentist adaptive enrichment designs
    Simon, Noah
    Simon, Richard
    BIOSTATISTICS, 2018, 19 (01) : 27 - 41
  • [8] Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials
    Chen, Yeh-Fong
    Yang, Yang
    Hung, H. M. James
    Wang, Sue-Jane
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 (04) : 592 - 604
  • [9] Placebo nonresponders: An experimental investigation on their unreliability over time
    Benedetti, Fabrizio
    Thoen, Wilma
    Shaibani, Aziz
    Arduino, Claudia
    JOURNAL OF PAIN, 2025, 28
  • [10] A COMPARISON OF PLACEBO RESPONDERS AND NONRESPONDERS IN SUBGROUPS OF DEPRESSIVE DISORDER
    BIALIK, RJ
    RAVINDRAN, AV
    BAKISH, D
    LAPIERRE, YD
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 1995, 20 (04): : 265 - 270